New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
10:14 EDTBANC, PPC, TKC, TEVA, SIGI, NSH, NS, LOW, INDB, TESOOn The Fly: Analyst Upgrade Summary
Banc of California (BANC) upgraded to Buy from Neutral at Sterne Agee... Independent Bank (INDB) upgraded to Outperform from Market Perform at Keefe Bruyette... Lowe's (LOW) upgraded to Outperform from Perform at Oppenheimer... NuStar Energy (NS) upgraded to Buy from Neutral at Goldman... NuStar GP Holdings (NSH) upgraded to Neutral from Sell at Goldman... Selective Insurance (SIGI) upgraded to Outperform from Market Perform at Keefe Bruyette... Teva (TEVA) upgraded to Neutral from Underweight at JPMorgan... Turkcell (TKC) upgraded to Buy from Neutral at UBS... Pilgrim's Pride (PPC) upgraded to Overweight from Equal Weight at Stephens... Tesco (TESO) upgraded to Overweight from Equalweight at Capital One.
Check below for free stories on BANC;INDB;LOW;NS;NSH;SIGI;TEVA;TKC;PPC;TESO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
18:20 EDTLOWLowe's CEO Niblock sells nearly $28M of company stock near record high
In regulatory filings, it was disclosed that Lowe's CEO Robert A. Niblock sold nearly $28M worth of company stock from September 9-11. Lowe's stock has been climbing steadily over the past three months, and it made both a 52-week and record high of $54.81 on Friday, September 19.
09:43 EDTINDBIndependent Bank management to meet with Guggenheim
Subscribe for More Information
September 18, 2014
10:40 EDTLOWPier 1 Imports falls to 12-month low after weak Q2, lowered outlook
Shares of home furnishings retailer Pier 1 Imports (PIR) hit a 12-month low after the company's second quarter results fell below analysts' consensus estimates and it reduced its fiscal 2015 earnings per share outlook. WHAT'S NEW: Pier 1 Imports reported Q2 EPS of 10c on revenue of $418.6M, missing analysts' consensus estimates of 14c and $426.02M, respectively. Same-store-sales for the quarter were up 4.5%. The retailer lowered its FY15 EPS outlook to 95c-$1.05 from $1.14-$1.22. Analysts' consensus estimates for FY15 EPS prior to the earnings report was $1.13. The company sees FY15 SSS in the mid-to-high single digits and gross profit, as a percentage of sales, are expected to be 40.5%-41.5%. Pier 1 Imports CEO Alex Smith said that he foresees online sales to surpass $400M in 2016. WHAT'S NOTABLE: During the company's conference call, Pier 1 Imports said that it expects to see improving merchandise margins in coming quarters with fewer coupons. The company noted plans to continue returning cash to shareholders in the form of dividends and share buybacks. ANALYST REACTION: This morning, Wells Fargo analyst Matt Neemer downgraded Pier 1 Imports to Market Perform from Outperform. He feels that the stock will be a difficult one to own in the medium term as the retailer moves towards a multi-channel approach. Neemer believes that the company has a difficult journey ahead as it cuts broad-based discounters, and he feels that consumers will take time to get accustomed to the new messaging. He cut his price target range to $15-$16 from $19-$20 for the company. Barclays analyst Alan Rifkin downgraded Pier 1 Imports to Equal Weight from Overweight due to slow revenue growth and heightened promotions. He feels that that the "soft" revenues could continue. He believes that the company's elongated online profitability pipeline and increased promotions are certain to be a burden on the business in ways that the company had not initially thought. Rifkin said that growing the top line will be even harder in the absence of promotions. He reduced his price target for shares to $14 from $18. Argus analyst Christopher Graja downgraded Pier 1 Imports to Hold from Buy due to the company's lower than anticipated Q2 earnings. He feels that in terms of the home furnishings market, companies such as Williams-Sonoma (WSM), Home Depot (HD) and Lowe's (LOW) are more "resilient" for shareholders. Pier 1 Imports was also downgraded to Hold from Buy at BB&T. PRICE ACTION: In morning trading, Pier 1 Imports fell $2.63, or 16.99%, to $12.90. Including today's pull back, the stock is down approximately 45.2% over the past 12 months. OTHERS TO WATCH: Other companies in the home furnishings space include Restoration Hardware (RH), and Bed Bath & Beyond (BBBY).
September 17, 2014
11:01 EDTTEVAActavis drops after NY AG seeks to block Alzheimer drug switch
Subscribe for More Information
10:00 EDTTESOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:05 EDTTEVAEagle Pharm says Teva requests motion to dismiss Bendamustine lawsuit
Subscribe for More Information
September 16, 2014
16:30 EDTTESOTesco initiated with a Buy at KeyBanc
Subscribe for More Information
September 12, 2014
09:01 EDTTEVATeva to present Copaxone gene expression analysis
Subscribe for More Information
08:06 EDTTEVATeva presents new clinical safety data in RRMS patients treated with Laquinimod
Teva (TEVA) and Active Biotech (ACTI) announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. In the pooled safety analysis, rates of adverse events, or AEs, and serious AEs were lower in the open-label extensions than in the core studies and less than three percent of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod.
08:03 EDTTEVATeva, Active Biotech present laquinimod follow-up data
Subscribe for More Information
September 11, 2014
12:05 EDTPPCUSDA lowers forecasts for 2014, 2015 meat production
Subscribe for More Information
09:31 EDTTEVATeva announces new data from Phase IIIb GLACIER study
Subscribe for More Information
03:27 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 10, 2014
14:25 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 9, 2014
19:07 EDTTESOWhite Eagle issues letter to Tesco board, criticizes $500M capex spending
White Eagle Partners, a shareholder of Tesco Corporation, sent a letter to the company's board criticizing management's proposed plans which suggest spending $250M in capex in tubular services over the next five years and an additional $250M for acquisitions. The letter calls on the board instead to institute a meaningful share buy-back plan in the near term. The letter said: "We were pleased to see the announcement of Quintana's planned resignation as president and CEO of Tesco Corporation. While we appreciated his work on the operational side, we were very disappointed with his flawed plans for the company. And we are particularly concerned with your announcement that we should expect "consistency in strategy" under Assing's management, who you indicate played a key role in the development of your current growth strategy. We believe that your proposed plan, which suggests $650M in capital to be deployed over the next five years, $250M for capex in tubular services, $250M for acquisitions, $100M for share buy-backs and $50M towards dividends, is flawed in a number of respects...Management expects the company to achieve $2.50 in EPS by 2018, which at current PE multiples suggest a price target north of $50 per share. If you believe your own projections, you would inevitably realize that the best allocation of capital is toward a share buy-back...We urge you to institute a meaningful share buy-back plan of at least $150M between now and your next annual meeting, which should still leave the company in a net cash position...Should you fail to modify your plans to take account of our suggestions, which we believe to be the best way to maximize shareholder value, we intend to pursue all appropriate shareholder actions to hold you accountable."
September 8, 2014
12:40 EDTTEVAFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
09:27 EDTTEVALeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:02 EDTTEVATeva completes Reslizumab Phase III program
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use